Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Thüringer Waid Forschungs GmbH (TWF) is a German biotechnology and research company specializing in the development of therapeutic and industrial products derived from Isatis tinctoria (Dyer's Woad). Established in 1991 and based in Neudietendorf, the company focuses on the extraction and characterization of bioactive compounds such as glucosinolates and tryptanthrin. TWF's research efforts are primarily directed toward oncology, specifically cancer prevention and therapy, as well as dermatology and anti-inflammatory applications. The company has historically collaborated with the Hans-Knöll-Institut (HKI) in Jena to advance the scientific understanding and clinical potential of woad-based natural products. Its work bridges the gap between traditional phytotherapy and modern pharmaceutical research, aiming to validate the medicinal properties of ancient dye plants.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Waid Forschungs.